- Home
- CHY vs CERT Comparison
CHY vs CERT Comparison
Compare CHY & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | CERT |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.9M | 860.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHY | CERT |
|---|---|---|
| Price | $12.35 | $4.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 216.9K | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $10.20 | $4.45 |
| 52 Week High | $13.11 | $13.88 |
Technical Indicators
Market Signals| Indicator | CHY | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 29.39 |
| Support Level | $11.28 | N/A |
| Resistance Level | $13.11 | $6.47 |
| Average True Range (ATR) | 0.25 | 0.31 |
| MACD | -0.09 | -0.14 |
| Stochastic Oscillator | 34.35 | 11.22 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.